Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

William Cheeley

Internal Medicine Columbia, SC Medical Doctor

NPI 1609396910 CMS profile 3350814

Internal Medicine Clinic, 1801 Sunset Drive, Columbia, SC 29203

Open in the dashboard

General payments

$3,489

209 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Cheeley of Columbia, SC is reported in the CMS Open Payments database as having received $3,489 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $377 19
2024 General $793 49
2023 General $646 45
2022 General $654 34
2021 General $743 46
2020 General $276 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Cheeley
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Cheeley were reported at $377. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Cheeley Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $276 $119 $33–$402 $114
2021 $743 $135 $37–$521 $132
2022 $654 $141 $42–$496 $149
2023 $646 $149 $45–$519 $160
2024 $793 $154 $47–$537 $164
2025 $377 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $575 49 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $404 22 payments
  3. Lilly USA, LLC $301 19 payments
  4. AstraZeneca Pharmaceuticals LP $260 18 payments
  5. Esperion Therapeutics, Inc. $170 8 payments
  6. AbbVie, Inc. $164 10 payments
  7. Pfizer Inc. $126 6 payments
  8. Medtronic, Inc. $119 2 payments
  9. Abbott Laboratories $109 5 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $106 6 payments
  11. Other $1,156 64 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,464 208 payments
  2. Education $25 1 payment
Products named General payments · program years 2020–2025
  1. Ozempic $534 46 payments
  2. RYBELSUS $532 46 payments
  3. JARDIANCE $347 19 payments
  4. MOUNJARO $269 17 payments
  5. FARXIGA $228 16 payments
  6. NURTEC ODT $173 10 payments
  7. NEXLETOL $170 8 payments
  8. Micra $103 1 payment
  9. Vascepa $96 5 payments
  10. Repatha $90 6 payments
  11. Other $1,735 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 134 drugs

Part D claims

10,731

Median for Internal Medicine: 777

Drug cost

$1,005,490

Median for Internal Medicine: $73,373

Branded share of claims

19.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 209 $216,432
Ozempic Semaglutide Brand 182 $204,710
Farxiga Dapagliflozin Propanediol Brand 89 $107,692
Jardiance Empagliflozin Brand 79 $98,095
Xarelto Rivaroxaban Brand 64 $79,549
Januvia Sitagliptin Phosphate Brand 25 $38,325
Tradjenta Linagliptin Brand 22 $24,177
Mounjaro Tirzepatide Brand 23 $23,774
Tresiba Flextouch U-200 Insulin Degludec Brand 13 $18,922
Myrbetriq Mirabegron Brand 20 $12,863

The 10 drugs with the highest cost, of 134 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$139,001

Of which drugs: $2,736

Medicare patients

596

Average age 75

Services billed

1,881

271 women, 325 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 42%
Ischemic heart disease 23%
Diabetes 22%
Atrial fibrillation 17%
Chronic kidney disease 16%
Cancer 14%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 30 30 $2,455

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $92
$92 182 —
RYBELSUS
  • Novo Nordisk Inc $90
$90 — —
MOUNJARO
  • Lilly USA, LLC $54
$54 23 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $48
$48 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $33
$33 89 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record